Prolight announced that its rights issue was fully subscribed, eliminating near-term financing risk and securing the capital needed to finalise the development, verification and pilot production of the Psyros™ system. The broad participation from the board, management and the company’s manufacturing partner (totalling SEK 20m) underscores confidence in Prolight’s strategy ahead of the critical commercial partnering discussions. With net proceeds of approximately SEK 100m before issue costs and set-offs and a new total share count of 1,203.6 million shares, we continue to find support for a fair value range of SEK 0.73–0.80 per share after the raise.

Financing secured to deliver on milestones
Prolight has announced that all 501.5 million shares offered in the rights issue were subscribed, with approximately 70% taken up by existing shareholders exercising their rights and the remaining 30% subscribed without rights. The rights issue raised approximately SEK 100 million before transaction costs and was completed without underwriters, highlighting strong interest in the company’s long-term potential. With this funding in place, Prolight can now proceed to optimise the system design, validate the pilot production lines and build inventory ahead of a European market launch.

Strong insider and partner commitment
A notable aspect of the outcome was the significant participation by the board, management and employees, who together invested approximately SEK 10 million, alongside ITL, Prolight’s contract manufacturing partner, committing an additional SEK 9.9 million. This combined commitment reinforces credibility and signals strong alignment of interests with shareholders. It also supports a robust negotiation position as the company advances discussions with potential commercial partners in H2 2025.

Valuation and outlook unchanged
Given the fully subscribed issue, our previous fair value range of SEK 0.73–0.80 per share remains intact, with an upside scenario of SEK 1.35 (USD 160m) supported by read-across from the recent SpinChip transaction. The successful financing further reduces execution risk, and we expect Prolight to intensify business development activities over the coming quarters as the final design freeze and clinical study preparations progress.

Read the full report here: https://www.emergers.se/prolight-l25/

Contact

Johan Widmark
johan@emergers.se

About Emergers

This is a press release from Emergers. 

DISCLAIMER
Information provided here or on Emergers' website emergers.se is not intended to be financial advice. Emergers receives compensation for writing about the company in question. The company has been given the opportunity to influence factual statements before publication, but forecasts, conclusions and valuation reasoning are Emergers' own. Articles of analysis shall not be construed as a recommendation or solicitation to invest in the companies described. Emergers cannot guarantee that the conclusions presented in the analysis will be met. Emergers cannot be held liable for either direct or indirect damages caused by decisions made on the basis of information in this analysis. Investors are encouraged to seek additional information as well as consult a financial advisor prior to any investment decision.

For more information and complete terms, please see emergers.se.

Attachments

Equity Research | PROLIGHT: Fully subscribed rights issue strengthens Psyros case ahead of commercial partnerships

Läs mer på Emergers